Skip to main content

Table 1 Baseline patient characteristics

From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

 

bb Lapatinib + Capecitabine

Characteristic

Brain metastasis (n = 58)

No Brain metastasis (n = 128)

Pvaluea

No Prior capecitabine (n = 95)

Prior capecitabine (n = 91)

Pvaluea

Total (n = 186†)

 

No.

%

No.

%

 

No.

%

No.

%

 

No.

%

Median age, yrs (range)

46.5

(27-70)

49

(27-71)

0.170

48

(27-71)

47

(29-70)

0.960

48

(27-71)

<50

38

(65.5)

67

(52.3)

0.1111

53

(55.8)

52

(57.1)

0.8832

105

(56.2)

≥50

20

(34.5)

61

(47.7)

 

42

(44.2)

39

(42.9)

 

82

(43.9)

Hormone receptor

ER + and/or PR+

28

(49.1)

45

(35.4)

0.103

36

(38.3)

37

(41.1)

0.764

73

(39.7)

ER- and PR-

29

(50.9)

82

(64.6)

 

58

(61.7)

53

(58.9)

 

111

(60.3)

Unknown

1

(1.7)

1

(0.8)

 

1

(1.0)

1

(1.1)

 

2

(1.1)

No. metastatic sites

1

5

(8.9)

17

(13.6)

0.174

14

(15.2)

8

(9.0)

0.042

22

(12.2)

2

15

(26.8)

47

(37.6)

 

37

(40.2)

25

(28.1)

 

62

(34.3)

≥ 3

36

(64.3)

61

(48.8)

 

41

(44.6)

56

(62.9)

 

97

(53.6)

Unknown

2

(3.4)

3

(2.3)

 

3

(3.2)

2

(2.2)

 

5

(2.7)

Pattern of metastasis

Visceral only

18

(31.6)

56

(45.5)

0.161

34

(37.8)

40

(44.4)

0.617

74

(41.1)

Non-visceral only

8

(14.0)

11

(8.9)

 

11

(12.2)

8

(8.9)

 

19

(10.6)

Both

31

(54.4)

56

(45.5)

 

45

(50.0)

42

(46.7)

 

87

(48.3)

Unknown

1

(1.7)

5

(3.9)

 

5

(5.3)

1

(1.1)

 

6

(3.2)

Prior capecitabine b

30

(51.7)

61

(47.7)

 

0

(0.0)

91

(48.9)

 

91

(48.9)

> 3 Prior chemotherapy regimens

22

(37.9)

45

(35.2)

 

10

(10.5)

57

(62.6)

 

67

(36.0)

Median duration of trastuzumab, wks (range)

35.4

(4.0-113.6)

20.6

(0.1-105.0)

0.016

27.3

(0.1-104.4)

21.6

(3.0-113.6)

0.252

24.1

(0.1-113.6)

Interval from last dose of trastuzumab prior to study entry, wks

Median (range)

11.6

(2.7-146.6)

20.9

(0.1-172.3)

0.365

7.7

(0.1-172.3)

24.9

(1.4-160.9)

0.001

14.6

(0.1-172.3)

< 4

3

(5.2)

16

(12.6)

0.341

14

(14.7)

5

(5.6)

<0.001

19

(10.3)

4 - 8

17

(29.3)

33

(26.0)

 

37

(39.0)

13

(14.4)

 

50

(27.0)

>8

38

(65.5)

78

(61.4)

 

44

(46.3)

72

(80.0)

 

116

(62.7)

Unknown

0

(0.0)

1

(0.8)

 

0

(0.0)

1

(1.1)

 

1

(0.5)

  1. a Fisher’s exact χ2 test for categorical variables and independent t-test for continuous variables; two-sided p-values.
  2. b Included 8 cases who had lapatinib during capecitabine.
  3. † Because of few information (only age and study date), 1 patient was excluded.
  4. ‘Unknown’ included missing values.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us